Larvol Delta - iTeos-Announces-Clinically-Meaningful-Objective-Response-Rate-Observed-at-Every-Dose-in-Followup-Interim-Analysis-of-GALAXIES-Lung201-Study-of-Belrestotug--Dostarlimab-in-FirstLine-PDL1-High-NonSmall-Cell-Lung-Cancer-Patients

Jemperli (dostarlimab-gxly) - GSK

belrestotug (EOS-448) - iTeos, GSK

https://www.globenewswire.com/news-release/2024/09/14/2946227/0/en/iTeos-Announces-Clinically-Meaningful-Objective-Response-Rate-Observed-at-Every-Dose-in-Follow-up-Interim-Analysis-of-GALAXIES-Lung-201-Study-of-Belrestotug-Dostarlimab-in-First-Li.html

Sep 14, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next